2023
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma
Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.Peer-Reviewed Original ResearchConceptsMedian overall survivalProgression-free survivalOverall survivalRecurrent glioblastomaAdverse eventsTherapy groupMedian progression-free survivalDevice-related adverse eventsSafety/feasibilitySerious adverse eventsFurther prospective studiesConcurrent therapyInvestigator's discretionStandard chemotherapyProspective studyTRIAL REGISTRATIONPatientsMonthsTreatmentHome-use deviceGlioblastomaWeeksSurvivalTotalGroupImaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original Research
2021
BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER
Kumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.Peer-Reviewed Original ResearchCSF tumor cellsLeptomeningeal diseaseBreast cancer patientsIntrathecal treatmentTumor cellsCase seriesOmmaya reservoirCancer patientsCerebrospinal fluidLarge prospective clinical trialsSmilow Cancer HospitalYale-New HavenMetastatic breast cancerProspective clinical trialsBarrow Neurological InstituteIntrathecal therapyTumor cell detectionFourth patientCancer HospitalTumor InstituteClinical managementClinical trialsBreast cancerTreatment responsePatientsQOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS
Blondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.Peer-Reviewed Original ResearchMalignant glioma patientsMedical marijuana programMalignant gliomasInactive patientsCannabis therapyActive patientsComplementary therapiesGlioma patientsOil supplementsCannabis productsMedian overall survivalSignificant palliative benefitSerious adverse eventsOverall survivalAdverse eventsDaily groupPalliative benefitCannabis treatmentPatientsPatient registration processOil groupTherapyGliomasMonthsSurvival
2019
ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.Peer-Reviewed Original ResearchSerious adverse eventsAdverse eventsRecurrent glioblastomaOverall survivalOutcome measuresDevice-related serious adverse eventsMedian overall survivalProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureLong-term treatmentMulti-center studyAnti-cancer therapyProspective studyTreatment groupsFeasible treatmentPatientsBrain cancerInvestigator's choiceInvestigational deviceChemotherapyGlioblastomaMonthsTreatmentACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.Peer-Reviewed Original ResearchAdverse eventsOutcome measuresDevice-related serious adverse eventsSerious adverse eventsProgression-free survivalSecondary outcome measuresCessation of treatmentFurther prospective studiesPrimary outcome measureStandard of careMulti-center studyMild dysesthesiaSurgical debulkingOverall survivalProspective studyClinical utilityFeasible treatmentPatientsBrain cancerInvestigational deviceMonthsTreatmentGBMSurvivalDebulkingINNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS.
Reddy N, Blondin N. INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS. Neuro-Oncology 2019, 21: vi135-vi135. PMCID: PMC6847258, DOI: 10.1093/neuonc/noz175.566.Peer-Reviewed Original Research
2018
ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.Peer-Reviewed Original ResearchDevice-related adverse eventsAdverse eventsOutcome measuresMaximal tumor debulkingSecond-line therapyProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureStandard of careMulti-center trialInvestigational medical deviceTreatment of glioblastomaClinical utility dataContinual therapyConcurrent therapyOverall survivalProspective studySafety profileTumor debulkingInterim safetyClinical utilityFeasible treatmentPatientsBrain cancerHOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL
Blondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.Peer-Reviewed Original ResearchQuality-adjusted life yearsHealth utility valuesLong-term survivorsLong-term survivalHealth utilityCondition-specific questionnaireEF-14 trialQuality of lifeHealth economic evaluationsGeneral population sampleStable diseaseAdverse eventsPreference-based measuresMultiple myelomaGBM patientsHealth state scenariosGlioblastoma patientsPatientsGBM treatmentSurvival rateLife yearsNew treatmentsUtility valuesDiagnosisHealth PanelQOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT
Blondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT. Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.Peer-Reviewed Original ResearchOverall survivalCannabis therapyTherapeutic cannabisPalliative useMedian ageCare treatmentGBM patientsSignificant adverse eventsTime period 2Time period 1Diagnosis dateAdverse eventsPatient ageSurvival benefitTumor characteristicsTherapeutic roleTreatment strategiesPatientsAnimal modelsHuman patientsGlioblastoma treatmentTherapeutic treatmentCannabis useTherapyGlioblastoma
2017
PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE
Blondin N. PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE. Neuro-Oncology 2017, 19: vi169-vi169. PMCID: PMC5692009, DOI: 10.1093/neuonc/nox168.688.Peer-Reviewed Original ResearchMalignant glioma patientsCannabis treatmentGlioma patientsCannabis therapyInitial experienceTherapeutic useBeneficial palliative effectBrain tumor symptomsCertain medical conditionsLow usePalliative useStandard therapyTumor symptomsOral sprayTherapeutic roleMalignant gliomasPalliative effectMild fatigueAnaplastic astrocytomaMedical conditionsAstrocytoma casesGlioblastoma patientsPatientsSide effectsAnimal models
2014
Primary CNS Lymphoma
Blondin N, Baehring J, Hochberg F. Primary CNS Lymphoma. 2014, 308-315. DOI: 10.1002/9781118589199.ch48.Peer-Reviewed Original ResearchPrimary CNS lymphomaCNS lymphomaPrimary central nervous system lymphomaCentral nervous system lymphomaNervous system lymphomaCerebral biopsyIntrathecal chemotherapySystem lymphomaInitial treatmentOcular lymphomaDifferential diagnosisRadiation therapyBrain tumorsLymphomaPatientsCurrent standardCorticosteroidsChemotherapyBiopsyPrognosisTherapyTumorsMultiple-choice questionsDiagnosisCareDiagnosis and management of periodic hypothermia
Blondin NA. Diagnosis and management of periodic hypothermia. Neurology Clinical Practice 2014, 4: 26-33. PMID: 29473588, PMCID: PMC5765588, DOI: 10.1212/01.cpj.0000437350.47610.3a.Peer-Reviewed Original ResearchPeriodic hypothermiaRecurrent episodesRare cases patientsAdditional clinical findingsProgressive confusionStereotyped syndromeCase patientsClinical findingsUnderlying disorderHypothalamic lesionsMetabolic disordersDrug toxicityHypothermiaClinical settingEnvironmental exposuresLevel of arousalEventual resolutionCore temperatureEpisodesDisordersDiaphoresisAsterixisThrombocytopeniaBradycardiaPatients
2012
Anaplastic Gliomas Radiation, Chemotherapy, or Both?
Blondin NA, Becker KP. Anaplastic Gliomas Radiation, Chemotherapy, or Both? Hematology/Oncology Clinics Of North America 2012, 26: 811-823. PMID: 22794285, DOI: 10.1016/j.hoc.2012.04.003.Peer-Reviewed Original ResearchPlantar Flexion with Noxious Dorsal Foot Stimulation in Brain Death
Hernandez AL, Blondin NA, Curiale G, Greer DM. Plantar Flexion with Noxious Dorsal Foot Stimulation in Brain Death. Neurocritical Care 2012, 17: 268-270. PMID: 22528275, DOI: 10.1007/s12028-012-9697-x.Peer-Reviewed Original ResearchConceptsBrain deathPlantar flexionSevere anoxic brain injuryAnoxic brain injuryArthroscopic knee surgeryBrain-dead patientsDorsal surfaceMethodsCase reportFoot stimulationCerebral perfusionNeurologic examinationNuclear scanDead patientsKnee surgeryBrain injuryNoxious stimulationPlantar stimulationAncillary testingGreat toeBrain scansTechnetium-99FlexionDeathStimulationPatients
2011
Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic Hypothermia
Blondin NA, Greer DM. Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic Hypothermia. The Neurologist 2011, 17: 241-248. PMID: 21881465, DOI: 10.1097/nrl.0b013e318224ee0e.Peer-Reviewed Original ResearchConceptsTherapeutic hypothermiaCardiac arrestNeurologic prognosisNeurologic outcomeGood neurologic outcomeCardiac arrest patientsNeurology practice parameterNeuromuscular blocking agentsCerebrospinal fluid biomarkersEligible patientsNeurologic prognosticationNeurophysiologic testingArrest patientsNeurophysiologic findingsPoor prognosisClinical examinationFluid biomarkersPharmacologic effectsBlocking agentPhysiologic effectsPractice parametersClinical examBetter outcomesPatientsPrognosis
2010
Thrombolysis in Right versus Left Hemispheric Stroke
Blondin NA, Staff I, Lee N, McCullough LD. Thrombolysis in Right versus Left Hemispheric Stroke. Journal Of Stroke And Cerebrovascular Diseases 2010, 19: 269-272. PMID: 20471856, DOI: 10.1016/j.jstrokecerebrovasdis.2009.04.012.Peer-Reviewed Original ResearchConceptsLeft hemispheric strokeRight hemispheric strokeT-PA administrationHemispheric strokeAcute strokeStroke centersEmergency departmentT-PAIntravenous recombinant tissue plasminogen activatorRecombinant tissue plasminogen activatorLarge community populationLarge prospective cohortPoor clinical outcomeT-PA useRight hemispheric syndromeTissue plasminogen activatorAffected hemisphereIschemic strokeProspective cohortClinical outcomesHemispheric syndromeStudy inclusionStudy populationPatientsStroke